ClinicalTrials.gg

Program

pasritamig

Also written as “JNJ-78278343” and “Pasritamig”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by Johnson & Johnson.

Furthest: phase 3, since Sep 4, 20255 company-led studies, 5 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson55 open or runningphase 3since Sep 4, 2025May 20, 2021Mar 31, 2027phase 1 · NCT04898634
  • Named in Johnson & Johnson’s own pipeline as pasritamig, phase 3, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2021First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04898634 · 216 enrolled · United States, China, France and more
  2. Oct 18, 2023Phase 1 study in Prostatic NeoplasmsNCT06095089 · 355 planned · United States, Australia, China and more
  3. Jul 22, 2025Phase 1 study in Prostatic NeoplasmsNCT07082920 · 140 planned · United States, United Kingdom
  4. Sep 4, 2025Phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT07164443 · 1,203 planned · United States, Australia, Belgium and more
  5. Nov 6, 2025Phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT07225946 · 800 planned · United States, Australia, Belgium and more

Ahead

  1. Mar 31, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT04898634
  2. Jun 21, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT06095089
  3. Nov 19, 2027Primary completion: phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT07225946
  4. Nov 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07082920

TargetBeta

“A T-cell redirecting agent and humanized immunoglobulin (Ig) G1 bispecific antibody targeting both human kallikrein-2 (hK2; KLK2) expressed on tumor cells and the CD3 receptor complex expressed on T-cells, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administra…”NCIt, read by Claude
“A T-cell redirecting agent and humanized immunoglobulin (Ig) G1 bispecific antibody targeting both human kallikrein-2 (hK2; KLK2) expressed on tumor cells and the CD3 receptor complex expressed on T-cells, ”NCIt, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07225946Prostatic Neoplasms, Castration-Resistant · United States, Australia, Belgium and more3RecruitingNov 19, 2027800
NCT07164443Prostatic Neoplasms, Castration-Resistant · United States, Australia, Belgium and more3RecruitingAug 18, 20281,203
NCT07082920Prostatic Neoplasms · United States, United Kingdom1RecruitingNov 30, 2027140
NCT06095089Prostatic Neoplasms · United States, Australia, China and more1RecruitingJun 21, 2027355
NCT04898634Prostatic Neoplasms · United States, China, France and more1Active, not recruitingMar 31, 2027216

How it is read

Names in the registry

  • “JNJ-78278343”, 3 entries
  • “Pasritamig”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.